OncoMatch/Clinical Trials/NCT07209111
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Is NCT07209111 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cetuximab and Calderasib for neoplasm malignant.
Treatment: Calderasib · Cetuximab — Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12c mutation
Prior therapy
Must have received: standard of care systemic treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Greater Baltimore Medical Center ( Site 1104) · Baltimore, Maryland
- START Midwest ( Site 1103) · Grand Rapids, Michigan
- Rutgers Cancer Institute of New Jersey ( Site 1100) · New Brunswick, New Jersey
- START Mountain Region ( Site 1106) · West Valley City, Utah
- Virginia Cancer Specialists ( Site 1102) · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07209111 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard of care systemic treatment.
Does this trial require KRAS?
Yes, KRAS g12c mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify